Veru (VERU) Other Non Operating Income (2012 - 2024)
Veru (VERU) posted quarterly Other Non Operating Income of -$1.4 million for Q3 2024, down 622.15% year-over-year from $266583.0 in Q4 2023, and down 573.26% quarter-over-quarter from $294122.0 in Q2 2024.
Veru (VERU) Other Non Operating Income (2012 - 2024) Analysis & Trends
Veru (VERU) has reported Other Non Operating Income for 13 consecutive years, with -$1.4 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Other Non Operating Income fell 622.15% year-over-year to -$1.4 million; the TTM figure through Sep 2024 stood at -$1.2 million (down 693.57% YoY), while the FY2024 annual figure was -$655526.0, down 214.25% from the prior year.
- Other Non Operating Income declined to -$1.4 million in Q3 2024 per VERU's latest filing, from $294122.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.3 million in Q1 2023 and bottomed at -$2.8 million in Q2 2023.
- Historically, Other Non Operating Income has averaged -$36409.9 across 5 years, with a median of -$29761.0 in 2021.
- Annual changes were most pronounced in 2023 — Other Non Operating Income soared 13843.93% — and 2024, when it slumped 622.15%.
- Veru's Other Non Operating Income stood at -$87971.0 in 2020, then soared by 66.17% to -$29761.0 in 2021, then surged by 3762.51% to $1.1 million in 2022, then slumped by 108.4% to -$91591.0 in 2023, then slumped by 1419.76% to -$1.4 million in 2024.
- Business Quant data shows VERU's Other Non Operating Income at -$1.4 million in Q3 2024, $294122.0 in Q2 2024, and $8645.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | 294,122.00 |
| Mar 31, 2024 | 8,645.00 |
| Dec 31, 2023 | -91,591.00 |
| Sep 30, 2023 | 266,583.00 |
| Jun 30, 2023 | -2.84 Mn |
| Mar 31, 2023 | 1.33 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | -250,142.00 |
| Jun 30, 2022 | 1.28 Mn |
| Mar 31, 2022 | -9,677.00 |
| Dec 31, 2021 | -29,761.00 |
| Sep 30, 2021 | -458,238.00 |
| Jun 30, 2021 | -34,540.00 |
| Mar 31, 2021 | -48,330.00 |
| Dec 31, 2020 | -87,971.00 |
| Sep 30, 2020 | 302,014.00 |
| Jun 30, 2020 | -53,334.00 |
| Mar 31, 2020 | 23,832.00 |
| Dec 31, 2019 | 42,554.00 |